Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 22Recruiting 21Active not recruiting 11Terminated 5Unknown 3Not yet recruiting 3Withdrawn 1No longer available 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Rare Tumour 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1

Interventions

Cisplatin 122Carboplatin 121Drug Therapy 118Bevacizumab 105Capecitabine 99Oxaliplatin 97Radiotherapy 95Paclitaxel 88Gemcitabine 88tislelizumab 87Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 65Fluorouracil 62sintilimab 59Injections 57Surgical Procedures, Operative 56Docetaxel 54anlotinib 51130-nm albumin-bound paclitaxel 48Immune Checkpoint Inhibitors 47fludarabine 46Standard of Care 45Pemetrexed 43Blood Specimen Collection 43Biopsy 43venetoclax 41lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × alectinib × Clear all
NCT07560410 2026-05-11

Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

China Medical University Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Sarcoma

Bone Neoplasms

NCT06709274 2024-11-29

MOTION-NSCLC

Guangdong Association of Clinical Trials

Phase NA Not yet recruiting
342 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting
200 enrolled

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡